Arxis, Inc. (ARXS) is a dynamic biotechnology company focused on developing cutting-edge therapeutics for complex diseases, leveraging a robust research and development framework. With a diverse drug pipeline targeting both rare and widespread conditions, Arxis emphasizes strategic partnerships and comprehensive clinical initiatives to drive innovation and improve patient outcomes. As it progresses through critical clinical trial phases, the company is well-positioned for substantial growth and value creation, making it an attractive proposition for institutional investors in the fast-evolving biotech sector.
| Revenue (TTM) | $1.67B |
| Gross Profit (TTM) | $827.39M |
| EBITDA | $533.53M |
| Operating Margin | 24.20% |
| Return on Equity | 1.51% |
| Return on Assets | 2.89% |
| Revenue/Share (TTM) | $4.07 |
| Book Value | $7.76 |
| Price-to-Book | 5.62 |
| Price-to-Sales (TTM) | 10.83 |
| EV/Revenue | 12.12 |
| EV/EBITDA | 55.32 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 20.70% |
| Shares Outstanding | $69.66M |
| Float | $66.81M |
| % Insiders | 4.03% |
| % Institutions | 39.66% |
Volatility is currently contracting
BLOOMFIELD, Conn., July 29, 2026 /PRNewswire/ -- Arxis, Inc. (NASDAQ: ARXS)(the "Company" or "Arxis"), a leading designer and manufacturer of proprietary, mission-critical electronic and mechanical engineered components, today reported financial results for the second quarter ended June 30, 2026.
BLOOMFIELD, Conn., July 16, 2026 /PRNewswire/ -- Arxis, Inc. (NASDAQ: ARXS) today announced that it will release its financial results for the second quarter of 2026 after the market closes on Wednesday, July 29, 2026.
Arxis, Inc. (ARXS) Q1 2026 Earnings Call Transcript
BLOOMFIELD, Conn., June 2, 2026 /PRNewswire/ -- Arxis, Inc. (NASDAQ: ARXS) (the "Company" or "Arxis"), a publicly-traded industrial compounder formed in partnership with Arcline Investment Management ("Arcline"), today announced it has entered into a definitive agreement to acquire Omnetics Connector Corporation ("Omnetics"), a leading designer and manufacturer of proprietary high-reliability Micro-D-Sub and Nano-D-Sub connectors and interconnect assemblies used in critical defense and space, commercial aerospace, and medical applications.
Arxis NASDAQ: ARXS reported a strong first quarter in its first earnings call as a public company, with management pointing to broad-based growth across defense and space, commercial aerospace and industrial technology, as well as a strengthened balance sheet following its initial public offering.
BLOOMFIELD, Conn., May 27, 2026 /PRNewswire/ -- Arxis, Inc. (NASDAQ: ARXS) (the "Company" or "Arxis"), a leading designer and manufacturer of proprietary, mission-critical electronic and mechanical engineered components, today reported financial results for the first quarter ended March 31, 2026.
BLOOMFIELD, Conn., May 14, 2026 /PRNewswire/ -- Arxis, Inc. (NASDAQ: ARXS) today announced that it will release its financial results for the first quarter of 2026 after the market closes on Wednesday, May 27, 2026.
Cheap space stocks used to sell under 4 times sales. Today, the cheapest space stocks cost more than 10x sales.
Arxis surged 39% on its IPO debut, reflecting strong investor appetite for its roll-up strategy in mission-critical aerospace components. ARXS now trades at a $17 billion valuation, equating to 10x sales and EBITDA multiples in the thirties, despite not matching peer margins. The business model mirrors TransDigm and Loar, leveraging acquisitions, pricing power, and operational efficiencies to drive growth and premium multiples.
Aerospace and defense parts maker Arxis' shares surged nearly 36% in their Nasdaq debut on Thursday, signaling growing appetite for defense and industrial listings as geopolitical tensions escalate.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ARXS and any ticker you trade — then tracks every position and per-strategy win rate.
